Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Neurolgy Institute for Brain Health and Fitness
Sponsor:
Collaborator:
DSM Nutritional Products, Inc.
Information provided by (Responsible Party):
Majid Fotuhi, MD, PhD, Neurolgy Institute for Brain Health and Fitness
ClinicalTrials.gov Identifier:
NCT01766180
First received: January 8, 2013
Last updated: August 27, 2013
Last verified: August 2013
  Purpose

The purpose of this study is to determine whether Fruitflow-II, Resveratrol (resVida), alone or in combination, are effective in the treatment of memory problems in adult patients with memory impairment. We also evaluate effects of these medications on blood flow to the brain and fitness, to find whether the possible improvement in memory is associated with the alterations in these parameters.


Condition Intervention
Memory Impairment
Drug: Fruitflow-II
Drug: resVida

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Association Between Fruitflow-II Treatment (Alone or in Combination With Resveratrol) and Changes in Cerebral Blood Flow, Fitness and Cognitive Function in Adults With Memory Complaints

Resource links provided by NLM:


Further study details as provided by Neurolgy Institute for Brain Health and Fitness:

Primary Outcome Measures:
  • Evidence of improvement in memory after treatment with Fruitflow-II, resVida (Resveratrol), alone or in combination [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

    The following tests will be used for evaluating cognitive function:

    1. Cambridge Neuropsychological Test Automated Battery (CANTAB). We use 5 tests which are mostly related to memory functioning including following:

      • Visual memory tests incuding (A) Paired Associates Learning (PAL) and (B) Pattern Recognition Memory (PRM)
      • Executive function, working memory and planning tests including (A) Stockings of Cambridge (SOC) and (B) Spatial Working Memory (SWM)
      • Semantic/verbal memory tests including (A) Verbal Recognition Memory (VRM)
    2. Trail-Making Test (TMT)
    3. Verbal Fluency Test


Secondary Outcome Measures:
  • Maximal VO2 (VO2 max) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Aerobic fitness (VO2 max) will be assessed by graded maximal exercise testing on a stationary bicycle. Oxygen uptake (VO2) will be measured from expired air samples to be taken at 30-s intervals until a maximal VO2 (VO2 max) is attained or to the point of test termination secondary to symptom limitation and/or volitional exhaustion. VO2 max will be defined as the highest recorded VO2 value when two of three criteria are satisfied: (1) a plateau in VO2 peak between two or more workloads; (2) a respiratory exchange ratio >1.00; and (3) a heart rate equivalent to their age-predicted maximum.

  • Blood Flow to the Brain [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Cerebral blood flow velocity will be measured in the middle cerebral artery (MCA) and basilar artery (BA) using Transcranial Doppler ultrasonography.


Estimated Enrollment: 80
Study Start Date: January 2013
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Placebo / Placebo
In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
Active Comparator: Fruitflow-II / Placebo
In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
Drug: Fruitflow-II
150 mg/day for 3 months, orally
Active Comparator: Placebo / resVida
In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
Drug: resVida
150 mg/day for 3 months, orally
Other Name: "resVida" is other name for Resveratrol.
Active Comparator: Fruitflow-II / resVida
In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
Drug: Fruitflow-II
150 mg/day for 3 months, orally
Drug: resVida
150 mg/day for 3 months, orally
Other Name: "resVida" is other name for Resveratrol.

Detailed Description:

Accumulating evidence suggests that tomato consumption has cardiovascular benefits, primarily through increasing blood flow in vivo; the active ingredient in tomato, or its extract (Fruitflow) have been shown to inhibit glycoprotein IIb/IIIa, similar to aspirin (which has antiplatelet activity and is used for secondary prevention of cardiovascular and cerebrovascular events in patients). Considering the fact that Fruitflow can improve the platelet function and peripheral blood flow, we hypothesized that Fruitflow can also increase the blood flow in the brain and thereby possibly enhance memory and cognitive function in middle-aged or elderly people who have memory complaints. Therefore, the initial goal of our study is to evaluate the effects of Fruitflow on brain blood and cardiovascular function by using Transcranial Doppler ultrasound (to check for changes in cerebral blood flow), cardiovascular fitness testing (to check for changes in VO2-max and stroke volume), and neurocognitive evaluation (to check for changes in memory and executive function).

Many pathways such as inflammation and oxidative stress are involved in the pathophysiology of memory loss with ageing. Recent studies have shown that a natural compound found in the skin of red grapes and also in wine, called "Resveratrol", have beneficial effects for prevention of cognitive decline by reducing inflammation and improving cardiovascular function. Therefore, our next goal is to evaluate whether administration of Resveratrol, by itself or in combination with Fruitflow, can improve brain blood flow, VO2-max, and cognitive performance.

Thus our clinical trial will have the following 4 arms: Fruitflow, Resveratrol, Fruitflow/Resveratrol combination, and placebo for each supplement.

The results of the study will potentially provide evidence that these natural supplements can have significant cardioprotective and neuroprotective properties in middle-aged and elderly adults.

Subjects (between 50 and 80 years old) complaining of memory problem who have MMSE (Mini-Mental State Examination) above 27 will be recruited from patients of Dr. Majid Fotuhi (PI at the Neurology Institute for Brain Health and Fitness). Flyers at the institute and advertisement in Baltimore will provide information about the opportunity to enroll in an observational study for 3 months, along with eligibility criteria. Participants will continue to receive routine and standard care, while data on outcome (i.e., dependent) variables and mediators will be collected over three study visits:

Day 1: at the onset of their participation: Assessment of memory and Cardiovascular Fitness Testing (CFT)

Day 2: Blood Test and Transcranial Doppler (TCD) Ultrasound at time 0 and 3 hours after taking the first dose of the supplements;

Month 3: Assessment of memory, Cardiovascular Fitness Testing, and Transcranial Doppler Ultrasound 3 months after daily treatment with supplements in each group.

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Between the ages of 50 and 80;
  2. Having a primary care physician;
  3. Ability to speak, read, and write English;
  4. Logical Memory subtest (of the Wechsler Memory Scale - IV [WMS-IV]) raw score one standard deviation or greater below the mean of a younger population;
  5. Be in stable overall health based on medical history and physical examination;
  6. Sedentary or moderately active (< 2 aerobic session / week);
  7. Suspend, for at least one month before participating in the study, the use of dietary supplements (fish oil, seed oils, ginkgo biloba, ginseng, resveratrol, fruit powder extracts and DHA; subjects who have high intake of these products are asked to take off these products for 4 weeks and after this washout period they will be recruited in the study). No more than one multivitamins per day is acceptable;
  8. Wine intake not more than 2 glasses per day

Exclusion Criteria:

  1. Patients reporting severe depression with or without suicidal ideation [Beck Depression Inventory (BDI) > 30 and BDI item #9 >1];
  2. Patients with a severe language or hearing and/or vision impairment;
  3. Pregnancy;
  4. Patients presenting with delirium, dementia, or cognitive impairment (Mini-Mental Status Examination score < 26);
  5. Current alcohol or substance abuse/dependence;
  6. Major neurological and psychiatric diseases including Parkinson's disease, Alzheimer's disease, epilepsy, multiple sclerosis, concussion/traumatic brain injury, schizophrenia, bipolar disorder, psychosis, eating disorders;
  7. Uncontrolled high blood pressure (> 180/100 mmHg) or a documented record of uncontrolled high blood pressure-related complications such as cerebral vascular disease (CVD), and/or large strokes with disability, uncontrolled diabetes mellitus (medical report of blood HbA1c > 7 during the last three months; in diabetic patients without this record HbA1c will be measured in the first blood testing), or history of major cardiopulmonary disease such as congestive heart failure, pulmonary disorders (COPD [emphysema or chronic bronchitis] and pulmonary embolism);
  8. Documented evidence of the following findings in the current medical history of subjects:

    8-1- Low platelet number (< 170 x 10^9/ L); 8-2- Hematocrit below 40% for males or 30% for females; 8-3- Haemoglobin below 120 g/L for males or 110 g/L for females; 8-4- Prothrombin time (PT) values outside normal range of approximately 10-16 s;

  9. Current hepatic failure, renal failure, bleeding disorders (hemophilia, Von Willebrand disease, esophageal varicoses);
  10. Subjects who have given 500 ml of blood or more for transfusion purposes in the past month before entry into the study
  11. Patients who take aspirin more than 325 mg/day
  12. Current medications for cognition such as acetylcholine esterase inhibitors (e.g., tacrine, donepezil, galantamine, rivastigmin) and memantine;
  13. Known history of allergies to tomatoes or tomato-based products;
  14. High habitual intake of tomatoes, grapes, and tomato-based products confirmed by food frequency questionnaire (>5 times per day). Subjects who have high intake of these products are asked to take off these products for 4 weeks and after this washout period they will be reconsidered to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01766180

Contacts
Contact: Majid Fotuhi, MD, PhD (410) 494-0191 mfotuhi@jhu.edu
Contact: Mehdi Ghasemi, MD (410) 494-0191 m82_ghasemi@yahoo.com

Locations
United States, Maryland
NeurExpand Brain Center, 1205 York Road, Suite 18 Recruiting
Lutherville, Maryland, United States, 21093
Contact: Majid Fotuhi, MD    410-494-0191    mfotuhi@jhu.edu   
Principal Investigator: Majid Fotuhi, MD, PhD         
Sub-Investigator: Mehdi Ghasemi, MD         
Sponsors and Collaborators
Neurolgy Institute for Brain Health and Fitness
DSM Nutritional Products, Inc.
Investigators
Principal Investigator: Majid Fotuhi, MD, PhD Neurology Institute for Brain Health and Fitness (NIBHF), Lutherville, MD 21093
Study Director: Mehdi Ghasemi, MD Neurology Institute for Brain Health and Fitness (NIBHF), Lutherville, MD 21093
  More Information

Additional Information:
No publications provided

Responsible Party: Majid Fotuhi, MD, PhD, Founder and Medical Chief Officer, Neurolgy Institute for Brain Health and Fitness
ClinicalTrials.gov Identifier: NCT01766180     History of Changes
Other Study ID Numbers: 2012-1048
Study First Received: January 8, 2013
Last Updated: August 27, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Neurolgy Institute for Brain Health and Fitness:
Memory
Fruitflow
Resveratrol (resVida)
Cerebral blood flow
Cardiopulmonary exercise test
Maximal VO2

Additional relevant MeSH terms:
Memory Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Hematologic Agents
Antimutagenic Agents
Anticarcinogenic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 24, 2014